Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Profit After Tax (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Profit After Tax for 16 consecutive years, with $44.8 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 244.06% to $44.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.3 million through Dec 2025, up 3034.77% year-over-year, with the annual reading at $124.5 million for FY2025, 3186.63% up from the prior year.
  • Profit After Tax hit $44.8 million in Q4 2025 for Ligand Pharmaceuticals, down from $117.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $117.3 million in Q3 2025 to a low of -$51.9 million in Q2 2024.
  • Historically, Profit After Tax has averaged $9.9 million across 5 years, with a median of -$245500.0 in 2022.
  • Biggest five-year swings in Profit After Tax: tumbled 2642.82% in 2023 and later soared 1735.15% in 2025.
  • Year by year, Profit After Tax stood at -$3.2 million in 2021, then plummeted by 447.43% to -$17.5 million in 2022, then surged by 213.54% to $19.9 million in 2023, then tumbled by 256.59% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025.
  • Business Quant data shows Profit After Tax for LGNDZ at $44.8 million in Q4 2025, $117.3 million in Q3 2025, and -$1.3 million in Q2 2025.